Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Well-Intentioned, But Can The Improved AAC Work For UK Medtechs?

Executive Summary

The newly enhanced Accelerated Access Collaborative (AAC) promises a more concerted effort to ensure health-care innovations reach end users. On paper, it looks good, but the medtech industry in the UK has seen several worthy efforts along similar lines ultimately amount to little. Health Enterprise East’s Dr. Anne Blackwood is reserving judgment.

You may also be interested in...

UK Plugs Into ‘Golden Period’ For Medtech Innovation

The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.

UK ABHI 2019: Correct Diagnosis Must Be Followed By Appropriate Therapy

The current hiatus in the Brexit debate has left room for other themes of clinical and commercial importance to the UK medtech industry to rise back to the surface of the national debate. The potential value of the Long Term Plan and innovation adoption and spread, among others, will share top billing at the ABHI’s 2019 UK Market Conference, in mid-June.

UK Plan To Speed Access To ‘Cutting-Edge’ Products

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts